This is part of the issue for me, and my major question on Tuesday.
LDX keep referencing Hologic charge $64.41 USD per fFN test.
LDX never tell shareholders if we will get lifetime royalties and if so - what %.
We could have fingers in 16 different pies, or none.
If LDX actually laid out in black and white our potential revenue - even if only by percentage - there would be a rerate of the SP.
Ann: Lumos Achieves First Phase 2 Milestone in Hologic Agreement, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.7¢ |
Change
-0.002(2.90%) |
Mkt cap ! $50.15M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.0¢ | 6.7¢ | $98.86K | 1.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 505996 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.9¢ | 183440 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| LDX (ASX) Chart |